TY - JOUR
T1 - Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs
AU - Hachiya, Atsuko
AU - Reeve, Aaron B.
AU - Marchand, Bruno
AU - Michailidis, Eleftherios
AU - Ong, Yee Tsuey
AU - Kirby, Karen A.
AU - Leslie, Maxwell D.
AU - Oka, Shinichi
AU - Kodama, Eiichi N.
AU - Rohan, Lisa C.
AU - Mitsuya, Hiroaki
AU - Parniak, Michael A.
AU - Sarafianos, Stefan G.
PY - 2013/9
Y1 - 2013/9
N2 - Drug combination studies of 4=-ethynyl-2-fluoro-2=-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.
AB - Drug combination studies of 4=-ethynyl-2-fluoro-2=-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.
UR - http://www.scopus.com/inward/record.url?scp=84882363875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882363875&partnerID=8YFLogxK
U2 - 10.1128/AAC.00283-13
DO - 10.1128/AAC.00283-13
M3 - Article
AN - SCOPUS:84882363875
SN - 0066-4804
VL - 57
SP - 4554
EP - 4558
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 9
ER -
